Immune-related adverse events (IRAE) of elderly patients (PTS) with advanced melanoma (AMEL) treated with checkpoint inhibitors (CI) in a community setting: The experience (EXP) at Kaiser Permanente (KP) California.

Thach-Giao Truong,Helen Moon,Timothy Chiu,Christopher Yamamoto,Michele M. Spence,Juraj Kavecansky,Fang Niu,Rita L. Hui

Immune-related adverse events (IRAE) of elderly patients (PTS) with advanced melanoma (AMEL) treated with checkpoint inhibitors (CI) in a community setting: The experience (EXP) at Kaiser Permanente (KP) California.

2018

Thach-Giao Truong
Helen Moon
Timothy Chiu
Christopher Yamamoto
Michele M. Spence
Juraj Kavecansky
Fang Niu
Rita L. Hui

e21583Background: CI have transformed treatment (TX) and survival for PTS with (w) AMEL. Our knowledge of TX outcomes (OUTC) and IRAEs is still largely informed by clinical trials enrolling younger...

Keywords:

Melanoma
Physical therapy
Immune system
Medicine
Adverse effect
community setting
Oncology
advanced melanoma
Clinical trial
Internal medicine
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations